Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19

Open Heart. 2020 Sep;7(2):e001350. doi: 10.1136/openhrt-2020-001350.
No abstract available

Keywords: anti-oxidants; inflammation; oxidative stress.

Publication types

  • Editorial

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects
  • Betacoronavirus / drug effects*
  • Betacoronavirus / immunology
  • Betacoronavirus / pathogenicity
  • COVID-19
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / virology
  • Drugs, Essential
  • Host-Pathogen Interactions
  • Humans
  • Ivermectin / administration & dosage*
  • Ivermectin / adverse effects
  • Pandemics
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents
  • Drugs, Essential
  • Ivermectin

Supplementary concepts

  • COVID-19 drug treatment